Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings-Reference-Cited by-同舟云学术

Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

Published:2017-03-11 Issue:5 Volume:10 Page:567-578
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Tomaszewski Erin L.,Moise Pierre,Krupnick Robert N.,Downing Jared,Meyer Margaret,Naidoo Shevani,Holmstrom Stefan

Funder

This study was funded by Astellas Pharma, Inc. and Medivation, Inc. (which was acquired by Pfizer, Inc. in September 2016), the co-developers of enzalutamide.

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1007/s40271-017-0227-y/fulltext.html

Reference41 articles.

1. Sternberg CN, Fizazi K, Saad F, Shore N, Heidenreich A, Hirmand M, et al. PROSPER: a phase III study of enzalutamide in non-metastatic (M0) castration-resistant prostate cancer (CRPC) patients [poster no. 802TiP]. ESMO Congress; 26–30 Sep 2014, Madrid.

2. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–9.

3. Hong JH, Kim IY. Nonmetastatic castration-resistant prostate cancer. Korean J Urol. 2014;55(3):153–60.

4. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology. 2002;11(4):307–26.

5. Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18(5):558–67.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Benefits of Green Tea in Prostate Cancer Prevention and Treatment: A Comprehensive Review;CHIN J INTEGR MED;2024

2. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer – a prospective multicenter study;BMC Palliative Care;2024-03-27

3. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23

4. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis;Future Oncology;2023-04

5. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial;European Urology;2023-03